DK0832069T3 - Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) - Google Patents
Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)Info
- Publication number
- DK0832069T3 DK0832069T3 DK95918722T DK95918722T DK0832069T3 DK 0832069 T3 DK0832069 T3 DK 0832069T3 DK 95918722 T DK95918722 T DK 95918722T DK 95918722 T DK95918722 T DK 95918722T DK 0832069 T3 DK0832069 T3 DK 0832069T3
- Authority
- DK
- Denmark
- Prior art keywords
- apolipoprotein
- apo
- biphenyl
- secretion
- inhibitors
- Prior art date
Links
- QVPQWJOZHWYLCJ-UHFFFAOYSA-N 2-phenyl-n-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide Chemical class C=1C=C2CNCCC2=CC=1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 QVPQWJOZHWYLCJ-UHFFFAOYSA-N 0.000 title 1
- 101710095342 Apolipoprotein B Proteins 0.000 title 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB1995/000448 WO1996040640A1 (fr) | 1995-06-07 | 1995-06-07 | DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0832069T3 true DK0832069T3 (da) | 2003-04-22 |
Family
ID=11004342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95918722T DK0832069T3 (da) | 1995-06-07 | 1995-06-07 | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5919795A (fr) |
| KR (1) | KR100225713B1 (fr) |
| AR (1) | AR003424A1 (fr) |
| AT (1) | ATE233734T1 (fr) |
| AU (1) | AU703493B2 (fr) |
| BG (1) | BG62442B1 (fr) |
| CO (1) | CO4440626A1 (fr) |
| DE (1) | DE69529849T2 (fr) |
| DK (1) | DK0832069T3 (fr) |
| DZ (1) | DZ2045A1 (fr) |
| IL (3) | IL135376A0 (fr) |
| MA (1) | MA23895A1 (fr) |
| MX (1) | MX9709914A (fr) |
| OA (1) | OA10363A (fr) |
| RO (1) | RO116897B1 (fr) |
| RU (1) | RU2141478C1 (fr) |
| TN (1) | TNSN96085A1 (fr) |
| TR (1) | TR199600481A2 (fr) |
| TW (1) | TW476756B (fr) |
| YU (1) | YU35296A (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199802163T2 (xx) * | 1996-04-30 | 1999-02-22 | Pfizer Inc. | 4'-Triflorometilbifenil-2-karboksilik asit |
| JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| CA2325358C (fr) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b |
| ES2240420T3 (es) * | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| JO2409B1 (en) * | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
| US6953671B2 (en) * | 2001-02-23 | 2005-10-11 | The Trustees Of Columbia University In The City Of New York | Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action |
| KR100575944B1 (ko) * | 2001-06-28 | 2006-05-02 | 화이자 프로덕츠 인코포레이티드 | 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜 |
| US7012077B2 (en) * | 2001-12-20 | 2006-03-14 | Hoffmann-La Roche Inc. | Substituted cyclohexane derivatives |
| CA2478909A1 (fr) * | 2002-03-13 | 2003-09-25 | Duane D. Miller | Composes tetrahydroisoquinoleine substitues, procedes de preparation et utilisation de ceux-ci |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| WO2005051945A1 (fr) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Composes heterocycliques utilises comme modulateurs des recepteurs actives proliferateurs du peroxysome (ppar), utiles dans le traitement et/ou la prevention de troubles modules par un ppar |
| AP2006003685A0 (en) | 2004-02-04 | 2006-08-31 | Pfizer Prod Inc | Substituted quinoline compounds |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法 |
| BRPI0607555A2 (pt) * | 2005-04-19 | 2009-09-15 | Surface Logix Inc | inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b |
| EP1890767A2 (fr) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combinaison d'un antagoniste des recepteurs cannabinoides-1 et d'un inhibiteur des proteines microsomales de transfert de triglycerides pour traiter l'obesite ou maintenir une perte de poids |
| SG10201406016SA (en) * | 2006-04-03 | 2014-11-27 | Stella Aps | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2007888A2 (fr) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Composition pharmaceutique comprenant des oligonucleotides antisens anti-miarn |
| GB0619176D0 (en) * | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
| CA2666191C (fr) * | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Composes antagonistes de l'arn pour la modulation de pcsk9 |
| AR063275A1 (es) * | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
| US8470791B2 (en) * | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
| DK2149605T3 (da) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| JP2010537958A (ja) * | 2007-08-30 | 2010-12-09 | サンタリス ファーマ アー／エス | Ｆａｂｐ４／ａｐ２を調節するためのｒｎａアンタゴニスト化合物 |
| EP2623599B1 (fr) * | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Oligonucléotides micromir |
| BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| CA2717792A1 (fr) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de maladies associees aux microarn |
| WO2010012667A1 (fr) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Modulation à médiation par micro-arn de facteurs stimulateurs de colonies |
| BRPI0919648A2 (pt) * | 2008-10-29 | 2015-12-08 | Hoffmann La Roche | novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1 |
| WO2010093601A1 (fr) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees |
| ES2599979T3 (es) * | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
| US20100280067A1 (en) * | 2009-04-30 | 2010-11-04 | Pakala Kumara Savithru Sarma | Inhibitors of acetyl-coa carboxylase |
| WO2010127208A1 (fr) * | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibiteurs de l'acétyl-coa carboxylase |
| EP2456870A1 (fr) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Oligomères anti-sens ciblant pcsk9 |
| MX2013005479A (es) * | 2010-11-15 | 2013-06-12 | Abbvie Inc | Inhibidores de nampt. |
| HUE048738T2 (hu) | 2013-06-27 | 2020-08-28 | Roche Innovation Ct Copenhagen As | Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg |
| US12453728B1 (en) | 2024-08-08 | 2025-10-28 | Redux Therapeutics, Llc | Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
| US3905982A (en) * | 1973-07-23 | 1975-09-16 | Searle & Co | 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds |
| JPS5237048B2 (fr) * | 1973-08-18 | 1977-09-20 | ||
| HU174697B (hu) * | 1976-12-30 | 1980-03-28 | Chinoin Gyogyszer Es Vegyeszet | Sposob poluchenija novykh proizvodnykh 6,7-dimetoksi-1,2,3,4-tetragidro-1-izokinolin-acetamida |
| EP0106140B1 (fr) * | 1982-09-10 | 1988-08-17 | The Wellcome Foundation Limited | Dérivés de l'acide benzoique |
| DK8386A (da) * | 1986-01-15 | 1987-07-09 | Tpo Pharmachim | Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme |
| DE3734385A1 (de) * | 1987-10-10 | 1989-04-20 | Hoechst Ag | Verwendung der (alpha)-modifikation von cis-naphthoylen-bis-benzimidazol zum pigmentieren von polyolefinen |
| GB9127306D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicyclic compounds and pharmaceutical compositions containing them |
| EA001539B1 (ru) * | 1996-11-27 | 2001-04-23 | Пфайзер Инк. | Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр) |
-
1995
- 1995-06-07 DK DK95918722T patent/DK0832069T3/da active
- 1995-06-07 DE DE69529849T patent/DE69529849T2/de not_active Expired - Fee Related
- 1995-06-07 AT AT95918722T patent/ATE233734T1/de not_active IP Right Cessation
- 1995-06-07 MX MX9709914A patent/MX9709914A/es not_active IP Right Cessation
- 1995-06-07 US US08/952,507 patent/US5919795A/en not_active Expired - Fee Related
-
1996
- 1996-04-19 TW TW085104696A patent/TW476756B/zh not_active IP Right Cessation
- 1996-05-30 IL IL13537696A patent/IL135376A0/xx not_active IP Right Cessation
- 1996-05-30 IL IL13537596A patent/IL135375A/en not_active IP Right Cessation
- 1996-05-30 IL IL13537796A patent/IL135377A0/xx not_active IP Right Cessation
- 1996-06-03 AR ARP960102871A patent/AR003424A1/es unknown
- 1996-06-05 DZ DZ960089A patent/DZ2045A1/fr active
- 1996-06-05 BG BG100637A patent/BG62442B1/bg unknown
- 1996-06-05 KR KR1019960020168A patent/KR100225713B1/ko not_active Expired - Fee Related
- 1996-06-06 YU YU35296A patent/YU35296A/sh unknown
- 1996-06-06 MA MA24265A patent/MA23895A1/fr unknown
- 1996-06-06 TR TR96/00481A patent/TR199600481A2/xx unknown
- 1996-06-06 TN TNTNSN96085A patent/TNSN96085A1/fr unknown
- 1996-06-06 AU AU54784/96A patent/AU703493B2/en not_active Ceased
- 1996-06-06 RU RU96111018A patent/RU2141478C1/ru not_active IP Right Cessation
- 1996-06-07 RO RO96-01181A patent/RO116897B1/ro unknown
- 1996-06-07 CO CO96029732A patent/CO4440626A1/es unknown
- 1996-06-07 OA OA60837A patent/OA10363A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL135377A (en) | 2001-05-20 |
| KR970003589A (ko) | 1997-01-28 |
| TR199600481A2 (tr) | 1996-12-21 |
| US5919795A (en) | 1999-07-06 |
| IL135375A (en) | 2001-07-24 |
| DZ2045A1 (fr) | 2002-07-21 |
| IL135377A0 (en) | 2001-05-20 |
| YU35296A (sh) | 1999-06-15 |
| MX9709914A (es) | 1998-03-31 |
| IL135376A (en) | 2001-05-20 |
| TNSN96085A1 (fr) | 2005-03-15 |
| TW476756B (en) | 2002-02-21 |
| IL135376A0 (en) | 2001-05-20 |
| AU703493B2 (en) | 1999-03-25 |
| MA23895A1 (fr) | 1996-12-31 |
| IL135375A0 (en) | 2001-05-20 |
| KR100225713B1 (ko) | 1999-10-15 |
| ATE233734T1 (de) | 2003-03-15 |
| DE69529849D1 (de) | 2003-04-10 |
| DE69529849T2 (de) | 2003-09-04 |
| BG100637A (bg) | 1997-03-31 |
| AR003424A1 (es) | 1998-08-05 |
| OA10363A (en) | 2001-11-15 |
| BG62442B1 (bg) | 1999-11-30 |
| RU2141478C1 (ru) | 1999-11-20 |
| AU5478496A (en) | 1996-12-19 |
| CO4440626A1 (es) | 1997-05-07 |
| RO116897B1 (ro) | 2001-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0832069T3 (da) | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) | |
| FI974440A0 (fi) | Bifenyyli-2-karboksyylihappo-tetrahydro-isokinolin-6-yyli-amidijohdannaisia, niiden valmistus ja niiden käyttö mikrosomaalistatriglyseridiä siirtävän proteiinin ja/tai apolipoproteiini B:n (Apo B) erittymiseen inhibiittoreina | |
| NO996491D0 (no) | 4-brom- eller 4-iod-fenylaminobenzhydroksamsyre-derivater og deres anvendelse som MEK-inhibitorer | |
| NO941679D0 (no) | Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse | |
| DK641589D0 (da) | N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer | |
| NO20005265L (no) | Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser | |
| DK1058725T3 (da) | Anvendelse af bakterier, som indeholder arginindeiminase, til induktion af apoptose og/eller reduktion af en inflammatorisk reaktion og farmaceutiske eller diætetiske præparater, der indholder sådanne bakterier | |
| DK118791A (da) | 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner, deres fremstilling og anvendelse som eller til fremstilling af laegemidler | |
| NO984878D0 (no) | Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere | |
| DK0910573T3 (da) | Nye aminosyrederivater og deres anvendelse som thrombininhibitorer | |
| DK326989D0 (da) | Alminoalkylaminocarbonylaminodiolaminosyrederivater og deres anvendelse som renininhibitorer | |
| DK1006110T3 (da) | Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler | |
| NO981522D0 (no) | Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister | |
| DK424385A (da) | Aminobenzopyranoner, deres fremstilling og anvendelse som antipsychotiske og anxiolytiske midler | |
| DK568287D0 (da) | Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer | |
| DK398986A (da) | Aminosyrederivater, fremgangsmaade til deres fremstilling og deres anvendelse | |
| DK123786D0 (da) | 4-(3-carboxy-3-diazo-2-oxopropyl)-azetidin-2-oner, deres fremstilling og anvendelse som carbapenemantibiotikummellemprodukter | |
| NO991589D0 (no) | Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler | |
| DK513188D0 (da) | Aminosyreestre, deres fremstilling og anvendelse som laegemidler | |
| NO893525D0 (no) | Amidoaminsalter av alkenylravsyrederivater, fremgangsmaater for deres fremstilling og deres anvendelse som korrosjonsinhibitorer. | |
| DK437287D0 (da) | 2,3-dihydrofuranderivater, deres fremstilling og deres anvendelse som mellemprodukter til fremstilling af tetrahydrofuranderivater | |
| DK198287A (da) | 3-amino-2-cyanacrylsyreestere, fremgangdsmaade til deres fremstilling og deres anvendelse som hebicider | |
| DK247484D0 (da) | Optisk aktive propionsyre-derivater,deres fremstilling og anvendelse | |
| DK0993439T3 (da) | 4-brom- eller 4-iod-phenyl-amino-benzhydroxamsyrederivater og deres anvendelse som MEK inhibitorer | |
| NO894229L (no) | 4-amino-3-acylkinolinderivater og deres anvendelse som inhibitorer av mavesyresekresjon. |